EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG

View source ↗

Summary

Rivastigmine Hexal has been authorised for dementia-related indications in the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine Hexal (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Hexal AG. Decision date: 19/08/2026